Regeneron Pharmaceuticals, Inc.

(NASDAQ Global Select)
Back to all articles
Very Bullish +78

Regeneron Pharmaceuticals (NASDAQ:REGN) Director Kathryn Guarini Sells ...

Analyst upgrade Dividend Earnings report AI-generated analysis

πŸ“ˆ Regeneron reported quarterly EPS of $20.07, beating analyst estimates of $16.51 by $3.56.

πŸ’° Revenue reached $5.12 billion for the quarter, up 36.3% compared to the same period last year.

πŸ“Š The company achieved a net margin of 28.51% and a return on equity of 16.01%.

πŸš€ Morgan Stanley raised its price target from $779.00 to $855.00 with an 'equal weight' rating.

πŸ”Ό UBS Group upgraded the stock from 'neutral' to 'buy' and set a price target of $978.00.

πŸ’΅ Cantor Fitzgerald increased its price target to $980.00 and assigned an 'overweight' rating.

πŸ“ˆ Argus upgraded the rating from 'hold' to 'buy' with a $850.00 price objective.

🏦 University of Texas Texas AM Investment Management Co. increased its stake by 66.1% in Q3.

πŸ“‰ Director Kathryn Guarini sold 400 shares for $360,000 under a Rule 10b5-1 trading plan.

πŸ’° A quarterly dividend of $0.94 per share will be paid on December 3rd to shareholders of record on November 20th.

πŸ“ˆ Institutional ownership stands at 83.31% with multiple firms increasing their holdings recently.

🧬 The company markets a diverse portfolio including Dupixent, Eylea, Libtayo, and Praluent.

Bullish Signals
  • Regeneron reported quarterly EPS of $20.07, significantly beating analyst estimates of $16.51.
  • Revenue surged to $5.12 billion for the quarter, representing a 36.3% year-over-year increase.
  • The company achieved a strong net margin of 28.51% and a return on equity of 16.01%.
  • Morgan Stanley raised its price target to $855.00, signaling continued analyst confidence.
  • UBS Group upgraded the stock from 'neutral' to 'buy' with a new price target of $978.00.
  • Cantor Fitzgerald boosted its price target to $980.00 and assigned an 'overweight' rating.
  • Argus upgraded the rating from 'hold' to 'buy' with a $850.00 price objective.
  • University of Texas Texas AM Investment Management Co. increased its stake by 66.1% in Q3.
  • Brighton Jones LLC raised its holdings by 24.9%, now owning shares valued at over $4 million.
  • Ethic Inc. boosted its position by 3.1%, increasing ownership to shares worth $12.56 million.
Full Analysis
Regeneron Pharmaceuticals (NASDAQ:REGN) reported strong quarterly financial results, posting $20.07 in earnings per share which significantly topped analyst consensus estimates of $16.51. The company generated revenue of $5.12 billion for the quarter, representing a 36.3% year-over-year increase compared to the prior period. Additionally, Regeneron achieved a net margin of 28.51% and a return on equity of 16.01%, demonstrating robust profitability and operational efficiency. Following the earnings release, the stock market reacted positively with several major investment banks upgrading their ratings or raising price targets. Morgan Stanley increased its price target to $855.00, while UBS Group upgraded the rating to 'buy' with a target of $978.00. Cantor Fitzgerald and Argus also boosted their respective price targets, reflecting growing institutional confidence in the company's growth trajectory. Institutional ownership remains high at 83.31%, with notable increases in stakes from firms such as University of Texas Texas AM Investment Management Co., Brighton Jones LLC, and Ethic Inc. during the third quarter. These accumulation trends suggest continued interest from long-term investors despite a recent insider sale by Director Kathryn Guarini, who sold shares under a pre-arranged trading plan.